Sandoz Suggests Coherus’ Cimerli Strategy Was ‘Unsustainable’
Expands On Plans To Withdraw And Reintroduce US Lucentis Biosimilar
In the wake of Formycon’s recent announcement that US marketing partner Sandoz would be pausing commercialization of the Cimerli rival to Lucentis that it recently took over from Coherus, Sandoz management has offered a few more details on its plans for the ranibizumab biosimilar.
